These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20858759)

  • 1. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer.
    Chen M; Hildebrandt MA; Clague J; Kamat AM; Picornell A; Chang J; Zhang X; Izzo J; Yang H; Lin J; Gu J; Chanock S; Kogevinas M; Rothman N; Silverman DT; Garcia-Closas M; Grossman HB; Dinney CP; Malats N; Wu X
    Cancer Prev Res (Phila); 2010 Oct; 3(10):1235-45. PubMed ID: 20858759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.
    Ke HL; Lin J; Ye Y; Wu WJ; Lin HH; Wei H; Huang M; Chang DW; Dinney CP; Wu X
    Ann Surg Oncol; 2015 Nov; 22(12):4104-10. PubMed ID: 25851338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
    Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
    Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer.
    Ke HL; Chen M; Ye Y; Hildebrandt MA; Wu WJ; Wei H; Huang M; Chang DW; Dinney CP; Wu X
    Carcinogenesis; 2013 May; 34(5):1006-11. PubMed ID: 23322153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin.
    Wei H; Kamat A; Chen M; Ke HL; Chang DW; Yin J; Grossman HB; Dinney CP; Wu X
    PLoS One; 2012; 7(6):e38533. PubMed ID: 22701660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes.
    Ryk C; Koskela LR; Thiel T; Wiklund NP; Steineck G; Schumacher MC; de Verdier PJ
    Redox Biol; 2015 Dec; 6():272-277. PubMed ID: 26298202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A six-week course of bacillus Calmette-Guérin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53.
    Oh JJ; Ji SH; Choi DK; Gong IH; Kim TH; Park DS
    Oncology; 2010; 79(5-6):440-6. PubMed ID: 21487231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment.
    Masson-Lecomte A; López de Maturana E; Goddard ME; Picornell A; Rava M; González-Neira A; Márquez M; Carrato A; Tardon A; Lloreta J; Garcia-Closas M; Silverman D; Rothman N; Kogevinas M; Allory Y; Chanock SJ; Real FX; Malats N;
    Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1144-50. PubMed ID: 27197286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
    Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
    Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
    Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
    BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
    Zhou Q; Ding W; Weng Y; Ding G; Xia G; Xu J; Xu K; Ding Q
    Chemotherapy; 2018; 63(4):191-197. PubMed ID: 30125887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study.
    Soria F; Milla P; Fiorito C; Pisano F; Sogni F; Di Marco M; Pagliarulo V; Dosio F; Gontero P
    World J Urol; 2016 Feb; 34(2):189-95. PubMed ID: 26026818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.